¹ú¼ÒÃâ·ÑÔÐǰÓÅÉú½¡¿µ¼ì²éTORCH¼ì²â½á¹û·ÖÎö
¡¾Õª Òª¡¿ Ä¿µÄ£ºÌ½¾¿¹ú¼ÒÃâ·ÑÔÐǰÓÅÉú½¡¿µ¼ì²éTORCH¼ì²â½á¹û¡£·½·¨£ºÑо¿Ñ¡È¡ÎÒÕ¾ÔÚ2014Äê1Ô¡«2016Äê1Ô½¡¿µ¼ì²éµÄÔÐǰ¸¾Å®1000Àý£¬¶ÔÆäÐÐøÁªÃâÒßÎü¸½·¨ÒÔ¼ì²âTORCHÌØÒìÐÔ¿¹Ì壨·çÕ¶¾RV-IgG¡¢¹ÐγæTOX-IgG¡¢¹ÐγæTOX-IgM¡¢¾Þϸ°û²¡¶¾CMV- IgG¡¢¾Þϸ°û²¡¶¾CMV- IgM£©£¬²¢½«ËùµÃ½á¹û½øÐжԱȷÖÎöÑо¿¡£½á¹û£º·çÕ¶¾RV-IgGÑôÐÔÂÊ95.2%¡¢¹ÐγæTOX-IgGÑôÐÔÂÊ2.2%¡¢¹ÐγæTOX-IgMÑôÐÔÂÊ6.5%¡¢¾Þϸ°û²¡¶¾CMV- IgGÑôÐÔÂÊ93.2%¡¢¾Þϸ°û²¡¶¾CMV- IgMÑôÐÔÂÊ0.4%¡£½áÂÛ£º¶ÔÔÐǰ¸¾Å®Ðйú¼ÒÃâ·ÑÔÐǰÓÅÉú½¡¿µ¼ì²é£¬²»½ö¿ÉÓÐЧ½µµÍÓ¤¶ù³öÉúȱÏÝ»úÂÊ¡¢½µµÍ¹¬ÄÚ¸ÐȾ»úÂÊ£¬¶øÇÒ»¹ÄÜÓÐЧÌá¸ß³öÉúÈË¿ÚËØÖÊ£¬ÊµÏÖÓÅÉúÓÅÓý£¬Òò¸Ã·½·¨ÖµµÃÔÚÁÙ´²ÉÏÍÆ¹ãºÍʹÓá£
¡¾¹Ø¼ü´Ê¡¿ ÔÐǰ ÓÅÉú½¡¿µ¼ì²é TORCH¼ì²â ½á¹û·ÖÎö ¾ÝÏà¹ØÊý¾ÝÏÔʾ£¬ÎÒ¹ú³öÉúȱÏÝÂÊÒԸߴï10%£¬ÎªÁË´Ó¸ù±¾É϶žø³öÉúȱÏÝ£¬ÎÒ¹ú´Ó2010ÄêÆÕ±é¿ªÕ¹¹ú¼ÒÃâ·ÑÔÐǰÓÅÉú½¡¿µ¼ì²éÊԵ㹤×÷£¬³ÉЧÏÔÖø¡£ÎªÁË̽¾¿¹ú¼ÒÃâ·ÑÔÐǰÓÅÉú½¡¿µ¼ì²éTORCH¼ì²â½á¹ûµÄÁÙ´²ÒâÒ壬¶Ô´ËѡȡÎÒÕ¾½ü2ÄêÃâ·Ñ½Ó´ýµÄ1000ÀýÔÐǰ¸¾Å®£¬¶ÔÆäÐÐøÁªÃâÒßÎü¸½·¨ÒÔ¼ì²âTORCHÌØÒìÐÔ¿¹Ì壬ÏÖ½«Ñо¿½á¹û±¨¸æÈçÏ¡£
1 ×ÊÁÏÓë·½·¨ 1.1 Ò»°ã×ÊÁÏ
Ñо¿Ñ¡È¡ÎÒÕ¾ÔÚ2014Äê1Ô¡«2016Äê1Ô½¡¿µ¼ì²éµÄÔÐǰ¸¾Å®1000Àý¡£ÄêÁäÔÚ20¡«35ËêÖ®¼ä£¬Æ½¾ùÄêÁä25.5¡À4.5Ë꣬ÆäÖÐ20¡«25ËêÓÐ520Àý£¬Õ¼±È52%£¬26¡«30ËêÓÐ300Àý£¬Õ¼±È30%£¬31¡«35ËêÓÐ180Àý£¬Õ¼±È18%£»Ì¥´ÎÔÚ1¡«3´Î£¬Æ½¾ùÌ¥´Î1.2¡À0.5´Î£»¸ßÖÐÒÔÉÏѧÀú170Àý£¬Õ¼±È17%£¬³õÖÐÒÔÉÏѧÀú700Àý£¬Õ¼±È70%£¬³õÖÐÒÔÏÂѧÀú130Àý£¬Õ¼±È13%£»Å©´åÈË¿Ú450Àý£¬Õ¼±È45%£¬·ÇÅ©´å550Àý£¬Õ¼±È55%¡£ 1.2 ·½·¨
¾ßÌå²Ù×÷·½·¨°üÀ¨£º£¨1£©»¤ÀíÈËÔ±±ØÐë×ÐϸѯÎÊÔи¾¼²²¡Ê·¡¢¼Ò×åÊ·¡¢ÒûʳƫºÃ¡¢Éú»î»·¾³¡¢´Óʹ¤×÷¡¢ÓÐÎÞ²»Á¼Ï°¹ßµÈ£»£¨2£©¶ÔÔи¾×ö½øÒ»²½¼ì²é£¬°üÀ¨²¡ÔÌå¼ì²é¡¢Ìå¸ñ¼ì²éÒÔ¼°¸¾¿Æ³¬Éù¼ì²é£»£¨3£©³éÈ¡Ôи¾¾²ÂöѪ3ml²¢¼°Ê±½øÐÐѪÇå·ÖÀ룬·ÖÀëºó±£´æÔÚ4¡æ»·¾³ÏÂÒÔ×÷½øÒ»²½¼ì²â£»£¨4£©±¾Ôº¼ì²âµÄÊÔ¼ÁºÐ¼°ÊÔ¼Á¾ùÀ´×Ô±±¾©ÏÖ´ú¸ß´ïÉúÎï¼¼ÊõÓÐÏÞ¹«Ë¾£¬¶ÔÔи¾ÐÐøÁªÃâÒßÎü¸½·¨ÒÔ¼ì²âTORCHÌØÒìÐÔ¿¹Ì壬¾ßÌå°üÀ¨£º·çÕ¶¾RV-IgG¡¢¹ÐγæTOX-IgG¡¢¹ÐγæTOX-IgM¡¢¾Þϸ°û²¡¶¾CMV- IgG¡¢¾Þϸ°û²¡¶¾CMV- IgM¡£ 1.3 ÆÀ¼Û±ê×¼
Ö÷Òª²â¶¨ISRÖµ£¬ÆäÖÐISRÖµ=£¨Ñù±¾Îü¹â¶È£¨OD£©/У
׼Ʒƽ¾ùODÖµ£©/УÕýÒò×Ó[1]¡£µ±ISRÖµ¡Ý1.1ʱΪÑôÐÔ¡¢ISRÖµ¡Ü0.9ΪÒõÐÔ¡¢ÈôISRÖµÔÚ0.9¡«1.1ʱÅжϿÉÒÉ£¬ÔòÐèÖØÐ¶ÔÑù±¾½øÐмì²â¡£ 1.4 ͳ¼ÆÑ§·ÖÎö
Ó¦Óà SPSS15.0 Èí¼þ·ÖÎö£¬ ¼ÆÁ¿×ÊÁϲÉÓþùÊý¡À±ê×¼²î£¨x¡Às£©±íʾ£¬ ×é¼ä±È½Ï²ÉÓÃT¼ìÑ飻¼ÆÊý×ÊÁϲÉÓðٷֱȱíʾ£¬ ×é¼ä±È½Ï²ÉÈ¡x2¼ìÑ飬ÒÔP<0.05Ϊ²îÒìÓÐͳ¼ÆÒâÒå¡£ 2 ½á¹û
·çÕ¶¾RV-IgGÑôÐÔÂÊ95.2%¡¢¹ÐγæTOX-IgGÑôÐÔÂÊ2.2%¡¢¹ÐγæTOX-IgMÑôÐÔÂÊ6.5%¡¢¾Þϸ°û²¡¶¾CMV- IgGÑôÐÔÂÊ93.2%¡¢¾Þϸ°û²¡¶¾CMV- IgMÑôÐÔÂÊ0.4%¡£¾ßÌåÊý¾ÝÏê¼û±í1 3 ÌÖÂÛ
ÎÒ¹ú´Ó2010Ä꽫¹ú¼ÒÃâ·ÑÔÐǰÓÅÉú½¡¿µ¼ì²é×÷ÎªÖØµãÏîÄ¿È«Ãæ¿ªÕ¹£¬Ä¿µÄÊÇ´Ó¸ù±¾ÉϽµµÍ³öÉúȱÏÝ·çÏÕ£¬Ìá¸ßÎÒ¹ú³öÉúÈË¿ÚËØÖÊ£¬Òò´ËÓÐЧ¶ÔÔÐǰ¸¾Å®½øÐÐTORCH¼ì²â½«ÏԵ÷dz£ÖØÒª¡£´Óҽѧ½Ç¶È¿´£¬TORCH¸ÐȾÓÖ±»³ÆÎªTORCH×ÛºÏÕ÷[2]£¬Ò»µ©»¼Õ߸ÐȾ½«µ¼ÖÂÔи¾³öÏÖÁ÷²ú¡¢Ôç²ú¡¢Ì¥ËÀ¸¹ÖУ¬ÑÏÖØÕßµ¼Ö²ú¸¾³öÏÖËÀÍö£¬¼´Ê¹Õý³£·ÖÃäÓ¤¶ùÒ²»á³öÏÖ·¢Óý²»Õý³£¡¢Éñ¾ÏµÍ³Ë𻵡¢ÖÇÕϵȲ¢·¢Ö¢£¬¶Ô²ú¸¾¼ÒÍ¥Ôì³É¼«´ó´ò»÷¡£
¾ÝÏà¹ØÑо¿·¢ÏÖ£¬TORCH¸ÐȾÔÚÁÙ´²ÖÐͨ³£¾ßÓÐÒþ²ØÐÔ£¬
Èô²»Í¨¹ýʵÑéÊÒ¼ì²âºÜÄÑÕï¶Ï³öÀ´¡£Ä¿Ç°ÁÙ´²Ö÷ҪʹÓÃøÁªÃâÒßÎü¸½·¨£¨ELISA£©À´½øÐйú¼ÒÃâ·ÑÔÐǰÓÅÉú½¡¿µ¼ì²é¡£·çÕ¶¾Ö÷ÒªÊÇͨ¹ýºôÎüµÀ½«²¡¶¾´«²¥£¬ÈôÉÔ¼Ó×¢Ò⣬Σº¦ÐÔ²»´ó£¬±¾´ÎÑо¿½á¹ûRV-IgG ÑôÐÔÂÊ95.2%£»¹ÐγæÊôÓÚÈËÐó¹²Í¬¸ÐȾÐÔ¼²²¡£¬·¢²¡Âʽϸߣ¬Ä¿Ç°·¢´ï¹ú¼ÒÒѸߴï30%×óÓÒ¡£¾ÝÏà¹ØÑо¿ÏÔʾ£¬Óж¯Îï½Ó´¥Ê·¸ÐȾTOX-IgMÑôÐÔÂÊΪ7.8%£¬ÎÞ¶¯Îï½Ó½Ó´¥Ê·¸ÐȾTOX-IgMÑôÐÔÂʽöΪ1%[3]¡£´ËÍ⣬ÏマÐȾ¹Ðγæ»úÂÊÒªÏÔÖø¸ßÓÚ´º¡¢Çï¡¢¶¬¡£±¾´ÎÑо¿¹ÐγæTOX-IgMÑôÐÔÂÊ6.5%£¬Ö÷ÒªÊÇÅ©´åÈË¿ÚÕ¼Ñо¿¶ÔÏó45%¡£¾Þϸ°û²¡¶¾±È½ÏÈÝÒ׸ÐȾ£¬ÓÈÆäÃâÒßÁ¦²îןüÈÝÒ׸ÐȾ¡£¾ÝÏà¹ØÑо¿·¢ÏÖ£¬µ±Ôи¾¸ÐȾ¾Þϸ°û²¡¶¾ºó£¬³¬¹ý90%Ôи¾ÊÇÎÞÃ÷ÏÔ²¡Ö¢£¬Ö»ÓÐ10%Ôи¾»á³öÏÖÇá΢Á÷¸ÐÖ¢×´¡£Èô¸ÐȾ¸Ã²¡¶¾ºó£¬Ö»ÓлÐÔ¾Þϸ°û²¡¶¾²Å»áµ¼ÖÂÌ¥¶ù³öÏÖ¸ÐȾ£¬Éú²ú»ûÐζù£¬Ä¿Ç°´«²¥»úÂÊÔ¼Õ¼20%¡£
×ÛÉÏËùÊö£¬¶ÔÔÐǰ¸¾Å®Ðйú¼ÒÃâ·ÑÔÐǰÓÅÉú½¡¿µ¼ì²é£¬²»½ö¿ÉÓÐЧ½µµÍÓ¤¶ù³öÉúȱÏÝ»úÂÊ¡¢½µµÍ¹¬ÄÚ¸ÐȾ»úÂÊ£¬¶øÇÒ»¹ÄÜÓÐЧÌá¸ß³öÉúÈË¿ÚËØÖÊ£¬ÊµÏÖÓÅÉúÓÅÓý£¬Òò¸Ã·½·¨ÖµµÃÔÚÁÙ´²ÉÏÍÆ¹ãºÍʹÓᣠ²Î¿¼ÎÄÏ×
[1] ²ÜÃÀ.4826 ÀýÓýÁ举ŮÔÐǰÆÚ TORCH ¸ÐȾ¼ì²âÓëÖÎÁÆÐ§¹û·ÖÎö[J].Öйúҽѧ´´Ð£¬2009£¬6£¨24£©£º67-68. [2] Qin W£¬ Hu D C£¬Pang H L.Detection the serum Ig M
and Ig G specific for TORCH in 1307 women in the period of pre-pregnancy and pregnancy[J].Chinese Journal of
Experimental and Clinial Infectious Diseases£¬2011£¬25£¨4£©£º292-294.
[3] ³ÂΰÔÀ£¬ºúÑàÇÙ.Õã½Äþ²¨µØÇø 18283 ÀýÔÐǰÓýÁ举Ů TORCH ¼ì²é½á¹û·ÖÎö[J].·ÅÉäÃâÒßѧÔÓÖ¾£¬2013£¬26£¨5£©£º668-670.